spacer
home > ebr > summer 2015 >
PUBLICATIONS
European Biopharmaceutical Review


Rate this article You must be a member of the site to make a vote.  
Average rating:
1
     

There are no comments in regards to this article.

spacer
News and Press Releases

Innovative Micro-Infusion Pump for Gerresheimer Subsidiary Sensile Medical Developed and Successfully Launched for EVER Pharma

Dsseldorf/Olten, July 03, 2019 Developed specially by Sensile Medical for EVER Pharma under the brand name D-mine, this wearable microinfusion pump recently received European CE certification and has already been launched in several European countries. The compact, patient-friendly infusion pump is used for the continuous subcutaneous administration of drugs to treat Parkinsons disease. The first micro pump from Gerresheimer subsidiary Sensile Medical to be available on the market, it gives Parkinsons patients greater independence in their day-today lives.
More info >>

White Papers

Microalgae Culture Using the DASGIP PBR4 Module for Illumination with a New Brunswick CelliGen 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIGs flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This years focus, A Look Back to the Future is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement